drugset / Trial / NCT00213005

Safety and Acceptability of Carraguard® in HIV Positive Women and Men

NCT00213005 ↗

RandomizedParallel-groupDouble-blindDiagnostic

Summary

The study objectives were to assess the mucosal safety of Carraguard® gel when applied vaginally once per day for 14 days by sexually abstinent and sexually active, HIV-positive women; to evaluate the effect of Carraguard® gel on the vaginal flora in these women; to evaluate the effect of Carraguard® gel on shedding of HIV-1 in the genital tract of these women; to evaluate the safety of Carraguard® gel when applied directly to the penis once per day for 7 days by sexually abstinent, HIV-positive men; to assess whether symptoms reported by female and male participants during the study may be related to the use of Carraguard® gel; and to examine dimensions of the acceptability of, and compliance with, the study and placebo products.

Timeline

Start
2002-06
Primary completion
—
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carraguard Other / unclassified — Other